Across the world, millions carry a silent infection that will, without intervention, become cancer — yet the tools to stop it already exist. Zainab Shinkafi-Bagudu, leading the Union for International Cancer Control, is pressing a foundational argument: liver cancer cannot be prevented without first eliminating hepatitis B and C, the infections responsible for the majority of cases globally. In Nigeria and across low-resource settings, structural barriers — inadequate vaccination, scarce screening, prohibitive costs, and stigma — keep millions undiagnosed and untreated, turning a preventable d
Oncodaily
· May 01, 2026
· health
· 3 min read
High
Sourcing: Verified
Hepatitis Elimination Key to Cancer Prevention, Says UICC President-Elect
Millions living with chronic hepatitis B and C remain undiagnosed and untreated, leading to preventable liver disease, cirrhosis, and cancer-related morbidity and mortality.
◉
Health & Medicine
8412 related articles
Retatrutide: Eli Lilly's Triple-Action Weight-Loss Drug Poised to Resh…
The Economic Times · 100% match
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight-Loss Treatment
Interesting Engineering · 99% match
Eli Lilly's Oral GLP-1 Pill Shows Promise for Diabetes and Weight Loss
TODAY · 99% match
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight Loss Drug
ScienceAlert · 99% match
Moderna's personalized mRNA melanoma vaccine shows promise in preventi…
CBS News · 99% match
Related Coverage
BBC News · Aug 25
School asbestos exposure linked to woman's death at 46, family claims
A woman died from mesothelioma at 46, likely exposed to asbestos at her Cardiff school decades earlier. Her family is su…
Future of Personal Health - · Aug 25 NGS Technology Transforms Uncertain Infections Into Actionable DiagnosesHybrid-capture NGS technology helps clinicians identify pathogens in diagnostically challenging cases by simultaneously …
The Guardian · Aug 25 Shark attack survivor Leah Stewart recalls 'monster' in first interview since losing armLeah Stewart, who lost her arm in a June shark attack at Coogee Beach, recalls the traumatic encounter in her first inte…
Education News Canada · Aug 25 Systemic racism, restrictive policies block Black Canadians from blood donationBlack Canadians face systemic barriers to blood donation despite critical need for ethnicity-matched blood for sickle ce…
Bias & Framing
⚖
Article presents UICC President-Elect's advocacy for hepatitis elimination as cancer prevention with minimal counterbalance, emphasizing disease burden and prevention gaps without exploring implementation challenges or alternative priorities.
Bias Direction
center-left
Confidence
MED
Advocacy framing through expert authority; presents hepatitis elimination as urgent public health imperative while emphasizing disparities in low-resource settings. Uses problem-solution structure that implicitly frames stronger action as necessary and uncontroversial.
major public health concern with serious consequences
leading cause of liver disease, cirrhosis, and liver cancer
receives limited attention despite being preventable, treatable, and curable
delay leads to greater morbidity and mortality
substantial public health challenge
central to cancer prevention efforts
gaps in service delivery
Resource allocation trade-offs: competing health priorities in LMICs with limited budgets
Cost-benefit analyses of hepatitis screening vs. other cancer prevention interventions
Government or healthcare system perspectives on implementation barriers beyond awareness
Private sector or pharmaceutical industry viewpoints on treatment accessibility
Perspectives from patients or communities on actual barriers to care beyond those listed
Counterarguments or skepticism regarding feasibility of elimination goals
Geopolitical Impact
🌎
UICC leadership advocates hepatitis elimination as cancer prevention strategy, highlighting disparities in low-resource nations where viral hepatitis drives liver cancer burden.
Escalation Risk
low
Confidence
HIGH
Nigeria
Sub-Saharan Africa
Asia
Low and middle-income countries (LMICs)
Taiwan
Global health governance shift toward integrated disease prevention; UICC positioning itself as convener between developed nations (vaccine/treatment access) and LMICs (disease burden); Taiwan hosting World Hepatitis Summit 2026 elevates its public health diplomacy role.
Similar to WHO's successful hepatitis B vaccination campaigns (1990s-2000s) that reduced transmission in high-coverage regions, but current gaps mirror historical inequities in vaccine distribution between wealthy and resource-limited nations.
Economic Lens
📈
Hepatitis elimination initiatives could drive significant healthcare spending in low-resource settings, creating opportunities in diagnostics, vaccines, and treatment sectors while reducing long-term cancer care costs.
Market Signal
bullish
Confidence
MED
Pharmaceutical and vaccine manufacturing
Diagnostic testing and medical devices
Healthcare services and hospital systems
Public health and disease prevention
Medical insurance and healthcare financing
Households in low-resource settings face increased out-of-pocket healthcare costs for hepatitis screening and treatment, but successful prevention programs could reduce catastrophic cancer treatment expenses and improve workforce productivity through disease prevention.
Governments in high-prevalence regions (Africa, Asia) likely to increase healthcare budgets for hepatitis screening, vaccination programs, and treatment access. International health organizations may establish funding mechanisms and regulatory frameworks for vaccine distribution and diagnostic standardization.